Company Profile

Panorama Research Inc
Profile last edited on: 1/19/23      CAGE: 47XM3      UEI: LYVHC3ARFRJ7

Business Identifier: Biotechnology Research & Development; biotechnology incubator
Year Founded
1991
First Award
1990
Latest Award
2019
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1230 Bordeaux Drive
Sunnyvale, CA 94089
   (408) 747-5201
   admin@pano.com
   www.pano.com
Location: Single
Congr. District: 17
County: Santa Clara

Public Profile

Panorama Research Inc. (PRI) is a privately owned biomedical research and development holding company. PRI effectively serves as an incubator of a number of technologies and pharmaceutical projects that subsequently were licensed to development partners or incorporated into PRI portfolio companies. The firm has spun out a large number of small firms of which some have gone to an IPO. 26 firms are listed as incorporated into PRI portfolio of companies of which 9 are/have been SBIR involved in their own right. The core expertise of PRI includes medicinal and organic chemistry, pharmacology, molecular and cell biology, plant molecular biology, oncology, immunology, infectious diseases and medicine.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $1,723,215
Project Title: Monoclonal Antibody for Autoimmune Disease
2018 2 NIH $1,723,683
Project Title: Novel NMDA-Targeted Therapy for Alzheimer's Disease
2018 2 NIH $1,717,413
Project Title: Rational Antibody Therapy for IPF
2016 1 NIH $224,981
Project Title: Novel Aminoadamantane Nitrates for the Treatment of Neurological Diseases
2016 1 NIH $224,981
Project Title: Hepcidin Antagonist Therapy for Anemia of Chronic Disease

Key People / Management

  James W Larrick -- President

  C Alverez

  Anthony Davies

  Jianmin Fang

  Charles Hardy

  Manley T Huang -- Director, Immunology

  Richard W Hyman

  Andrew R Mendelsohn

  Andrew R Mendelson -- Director, Molecular Biology and Protein Engineering

  John Wages -- Director, Business Development

  Yuqiang Wang -- Director, Organic and Medicinal Chemistry

  David S Wilson

  Susan C Wright -- Director, Cell Biology

Company News

There are no news available.